Glossary entry (derived from question below)
anglais term or phrase:
any disclaimer
français translation:
une renonciation éventuelle (de la concession ou du délai de prorogation du brevet)
Added to glossary by
NikkoTh
May 20, 2020 05:51
4 yrs ago
31 viewers *
anglais term
any disclaimer
anglais vers français
Autre
Droit (général)
Dans ce context
Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 818 days.
Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 818 days.
Proposed translations
(français)
References
| Disclaimers (US patent law) |
Eliza Hall
|
Proposed translations
+1
4 heures
Adrian MM.
Autriche
Autriche
Native in anglais
Specializes in field
Autriche
Retd.T&I, Barrister & Austro-Advokat
Native in: anglais (Variants: Scottish, British) 
Works in: espagnol vers anglais, anglais vers espagnol, français vers anglais, and 5 more.
Related KudoZ points
:
35
Selected
une renonciation éventuelle (de la concession ou du délai de prorogation du brevet)
subject to: sous réserve de
I thin that disclaimer - in US patent sense of the term - is nowt to do with a disclaimer of liability.
I thin that disclaimer - in US patent sense of the term - is nowt to do with a disclaimer of liability.
Example sentence:
A terminal disclaimer is a process by which a patent's term is shortened because it duplicates the claims of another patent which expires sooner.
In United States patent law, a statutory disclaimer is a statement in writing, recorded in the United States Patent and Trademark Office, disclaiming a complete claim of a patent or disclaiming a term, or terminal part of a term, of a patent granted or to
4 KudoZ points awarded for this answer.
-1
25 minutes
Yassine El Bouknify
Maroc
Maroc
Maroc
Literature,Marketing & Legal Translation
Native in: arabe (Variants: Kuwaiti, Najdi, Standard-Arabian (MSA), Hassaniya, Moroccan, UAE) 
, Berbère (autre) (Variants: Tashelhit , Riffian, Central Atlas Tamazight, Tamazight , Standard Moroccan Tamazight, Tarifit )
Works in: anglais vers arabe, français vers arabe, arabe vers anglais, and 21 more.
toute avis de non-responsabilité
toute avis de non-responsabilité
Peer comment(s):
| disagree |
Eliza Hall
: This would work in many other contexts, but not in patent law (see discussion).
10 heures
|
-1
2 heures
Samuel Clarisse
France
France
Native in français
France
Always keeping in mind the audience
Native in: français (Variants: Canadian, Belgian, Luxembourgish, Standard-France, Swiss)
Works in: anglais vers français, espagnol vers français
Related KudoZ points
:
58
Aucune responsabilité ne pouvant être engagée
Variantes:
Ne pouvant faire l'objet d'aucune responsabilité
Exonéré de toute responsabilité
Ne pouvant faire l'objet d'aucune responsabilité
Exonéré de toute responsabilité
Peer comment(s):
| disagree |
Eliza Hall
: This would work in many other contexts, but not in patent law (see discussion).
9 heures
|
-1
3 heures
sous réserve de tout avis de dégagement de responsabilité
-
Peer comment(s):
| disagree |
Eliza Hall
: This would work in many other contexts, but not in patent law (see discussion).
8 heures
|
-1
20 heures
Francois Boye
États-Unis
États-Unis
Native in français
États-Unis
An economic geek with social skills
Native in: français
Works in: anglais vers français, français vers anglais, espagnol vers anglais, and 1 more.
Related KudoZ points
:
199
sous réserve de toute suspension de la loi statuant sur la duréee des brevets
A terminal disclaimer does not negate Patent Term Extension that has been granted under 35 U.S.C. 156.[11] In a pharmaceutical patent dispute, Teva argued that Wyeth’s patent on zaleplon drug products (Sonata) had expired because of a terminal disclaimer. Wyeth (and its exclusive licensee King) argued that patent’s term was ongoing because of a Patent Term Extension due to FDA regulatory review delay. Under 35 U.S.C. 156(a), the term of a patent "shall be extended" after a series of provisions are satisfied. The district court found the language of the statute unambiguous and gives the court "no discretion".
Thus, if the enumerated conditions are satisfied, the patentee is entitled to a term extension calculated pursuant to Section 156. Teva's motion to dismiss was consequently denied because "a terminally disclaimed patent is eligible for extension under [Section] 156." The case is interesting because the patentee in the first instance had expressly disclaimed term subsequent to 2003 to get the patent granted. However, the holding of this case does not apply to Patent Term Adjustment granted under 35 U.S.C. 154. Such term adjustments will be subject to any terminal disclaimer that has been filed.[12]
Source: Wikipedia
--------------------------------------------------
Note added at 1 day 9 hrs (2020-05-21 15:43:06 GMT)
--------------------------------------------------
duréee = duréee de validité. Cette durée détetermine la date finale de la validité
Thus, if the enumerated conditions are satisfied, the patentee is entitled to a term extension calculated pursuant to Section 156. Teva's motion to dismiss was consequently denied because "a terminally disclaimed patent is eligible for extension under [Section] 156." The case is interesting because the patentee in the first instance had expressly disclaimed term subsequent to 2003 to get the patent granted. However, the holding of this case does not apply to Patent Term Adjustment granted under 35 U.S.C. 154. Such term adjustments will be subject to any terminal disclaimer that has been filed.[12]
Source: Wikipedia
--------------------------------------------------
Note added at 1 day 9 hrs (2020-05-21 15:43:06 GMT)
--------------------------------------------------
duréee = duréee de validité. Cette durée détetermine la date finale de la validité
Peer comment(s):
| disagree |
Eliza Hall
: No. See the reference I posted. It's not subject to the law but subject to any disclaimers made.
1 jour 14 heures
|
Reference comments
11 heures
Eliza Hall
États-Unis
États-Unis
Native in anglais
Specializes in field
États-Unis
Lawyer-Translator-Certified Interpreter
Native in: anglais (Variants: US, Scottish, Canadian, Irish, British, UK)
Works in: français vers anglais, anglais vers français
Related KudoZ points
:
80
Reference:
Disclaimers (US patent law)
35 U.S.C. 253 Disclaimer.
(a) IN GENERAL.—Whenever a claim of a patent is invalid the remaining claims shall not thereby be rendered invalid. A patentee, whether of the whole or any sectional interest therein, may, on payment of the fee required by law, make disclaimer of any complete claim, stating therein the extent of his interest in such patent. Such disclaimer shall be in writing and recorded in the Patent and Trademark Office, and it shall thereafter be considered as part of the original patent to the extent of the interest possessed by the disclaimant and by those claiming under him.
(b) ADDITIONAL DISCLAIMER OR DEDICATION.—In the manner set forth in subsection (a), any patentee or applicant may disclaim or dedicate to the public the entire term, or any terminal part of the term, of the patent granted or to be granted.
37 CFR 1.321 Statutory disclaimers, including terminal disclaimers.
(a) A patentee owning the whole or any sectional interest in a patent may disclaim any complete claim or claims in a patent. In like manner any patentee may disclaim or dedicate to the public the entire term, or any terminal part of the term, of the patent granted....
Pre-AIA 37 CFR 1.321 Statutory disclaimers, including terminal disclaimers.
*****
(b) An applicant or assignee may disclaim or dedicate to the public the entire term, or any terminal part of the term, of a patent to be granted.
https://www.uspto.gov/web/offices/pac/mpep/s1490.html
--------------------------------------------------
Note added at 11 hrs (2020-05-20 17:12:36 GMT)
--------------------------------------------------
And an example:
"In Merck & Co. v. Hi-Tech Pharmacal (06-1401) , the Court of Appeals for the Federal Circuit looked at the question of whether a patent term extension under the Hatch-Waxman Act, 35 U.S.C. § 156, may be applied to a patent subject to a terminal disclaimer under 35 U.S.C. § 253, filed to overcome an obviousness-type double-patenting rejection....
Merck had filed a patent application covering carbonic anhydrase inhibitors, including dorzolamide, which is the active ingredient in Trusopt®, a drug used to treat glaucoma.. That patent application eventually issued as United States Patent No. 4,797,413 but during prosecution, the examiner rejected all claims on the ground of obviousness-type double patenting over the claims of an earlier patent owned by Merck, U.S. Patent No. 4,677,115.
To overcome this rejection, Merck filed a terminal disclaimer that disavowed any term of the ’413 patent that would extend beyond June 30, 2004, the original term of the ’115 patent (17 years from its date of issue). The filing of the terminal disclaimer was accepted by the Examiner and the patent was granted...."
http://www.patentbaristas.com/archives/2007/03/30/patent-ter...
(a) IN GENERAL.—Whenever a claim of a patent is invalid the remaining claims shall not thereby be rendered invalid. A patentee, whether of the whole or any sectional interest therein, may, on payment of the fee required by law, make disclaimer of any complete claim, stating therein the extent of his interest in such patent. Such disclaimer shall be in writing and recorded in the Patent and Trademark Office, and it shall thereafter be considered as part of the original patent to the extent of the interest possessed by the disclaimant and by those claiming under him.
(b) ADDITIONAL DISCLAIMER OR DEDICATION.—In the manner set forth in subsection (a), any patentee or applicant may disclaim or dedicate to the public the entire term, or any terminal part of the term, of the patent granted or to be granted.
37 CFR 1.321 Statutory disclaimers, including terminal disclaimers.
(a) A patentee owning the whole or any sectional interest in a patent may disclaim any complete claim or claims in a patent. In like manner any patentee may disclaim or dedicate to the public the entire term, or any terminal part of the term, of the patent granted....
Pre-AIA 37 CFR 1.321 Statutory disclaimers, including terminal disclaimers.
*****
(b) An applicant or assignee may disclaim or dedicate to the public the entire term, or any terminal part of the term, of a patent to be granted.
https://www.uspto.gov/web/offices/pac/mpep/s1490.html
--------------------------------------------------
Note added at 11 hrs (2020-05-20 17:12:36 GMT)
--------------------------------------------------
And an example:
"In Merck & Co. v. Hi-Tech Pharmacal (06-1401) , the Court of Appeals for the Federal Circuit looked at the question of whether a patent term extension under the Hatch-Waxman Act, 35 U.S.C. § 156, may be applied to a patent subject to a terminal disclaimer under 35 U.S.C. § 253, filed to overcome an obviousness-type double-patenting rejection....
Merck had filed a patent application covering carbonic anhydrase inhibitors, including dorzolamide, which is the active ingredient in Trusopt®, a drug used to treat glaucoma.. That patent application eventually issued as United States Patent No. 4,797,413 but during prosecution, the examiner rejected all claims on the ground of obviousness-type double patenting over the claims of an earlier patent owned by Merck, U.S. Patent No. 4,677,115.
To overcome this rejection, Merck filed a terminal disclaimer that disavowed any term of the ’413 patent that would extend beyond June 30, 2004, the original term of the ’115 patent (17 years from its date of issue). The filing of the terminal disclaimer was accepted by the Examiner and the patent was granted...."
http://www.patentbaristas.com/archives/2007/03/30/patent-ter...
Peer comments on this reference comment:
| neutral |
Francois Boye
: which disclaimer do you choose? https://www.uspto.gov/web/offices/pac/mpep/s1490.html
5 heures
|
| agree |
Daryo
8 heures
|
Something went wrong...